



350 - 4243 Glanford Ave. Victoria, BC Canada V8Z 4B9  
Tel: (250) 744-2811 Fax: (250) 744-2877 www.stressgen.com

## STRESSGEN FILES FINAL PROSPECTUS FOR \$45.5 MILLION PUBLIC OFFERING

FOR IMMEDIATE RELEASE

OCTOBER 10<sup>th</sup>, 2000

**Victoria, British Columbia** - StressGen Biotechnologies Corp. (TSE: SSB) announced today that it has filed a final prospectus relating to the public offering of 6,500,000 Common shares at a price of CDN\$7.00 per share. This represents an additional 500,000 Common shares over the number offered in the preliminary prospectus. In addition, StressGen has granted the underwriters an option to purchase an additional 975,000 Common shares at CDN\$7.00 per share to cover over-allotments. Gross proceeds of this offering are CDN\$45,500,000, prior to exercise of the over-allotment option.

The underwriting syndicate for the offering was led by BMO Nesbitt Burns Inc., and included CIBC World Markets Inc. and Goepel McDermid Inc.

The net proceeds of this offering will be used primarily to fund the Company's development program for its lead product candidate HspE7. In addition, a portion of the funds will be used to drive the research and development of new product development opportunities, acquisition of complementary products or technologies, corporate expansion or relocation of its facilities, working capital and for general corporate purposes.

StressGen's lead product HspE7 targets a variety of precancerous and cancerous conditions caused by Human Papillomavirus (HPV). The Company has active Phase II HspE7 studies in women with high-grade cervical dysplasia and cervical cancer, as well as a Phase II study in anal dysplasia. In addition, StressGen plans to initiate a Phase II HspE7 study in genital warts and a Phase III HspE7 study in anal dysplasia before the end of the year.

StressGen Biotechnologies Corporation is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of virally-induced infections and related cancers. StressGen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis B. Through its Biochemical Division, StressGen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

-30-

Contact: Elisabeth Whiting, Director, Corporate Communications & Investor Relations  
StressGen Biotechnologies, 350-4243 Glanford Ave. Victoria, BC V8Z 4B9  
Tel: 250-744-2811 Fax: 250-744-3331 [ewhiting@stressgen.com](mailto:ewhiting@stressgen.com)

*This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "will", "intends", "plans", "expects" and words of similar import. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company's ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company's Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.*

###